Is Pediatrix Medical Group, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Pediatrix Medical Group, Inc. moved from attractive to very attractive, indicating a strong positive outlook. The company is currently undervalued, supported by a P/E ratio of 8, an EV to EBITDA of 7.17, and a PEG ratio of 0.19, all of which suggest that the stock is trading at a significant discount relative to its earnings growth potential. In comparison, Hims & Hers Health, Inc. has a much higher P/E ratio of 54.76, while Addus HomeCare Corp. is at 22.05, highlighting Pediatrix's relative value in the market.
Recent performance shows that Pediatrix Medical Group has outperformed the S&P 500, with a year-to-date return of 25.38% compared to the S&P 500's 13.30%. This strong performance, coupled with its attractive valuation ratios, reinforces the conclusion that the stock is undervalued in the current market environment.